Samuel Moed is a recently retired executive from Bristol Myers Squibb (BMS; NYSE: BMY), a global biopharma company focused on innovative therapeutics. In his most recent capacity as Senior Vice President, Corporate Strategy, Samuel led the strategic direction of the company with close linkage to all of its major businesses, functions, and geographies. Recent focus was on the $90 billion acquisition and integration of Celgene by BMS. Previously, Samuel oversaw strategy for BMS’s Worldwide Pharmaceuticals Group, encompassing a range of global strategic initiatives, and managed a global portfolio of strategic alliances. He also led a number of businesses including as President of U.S. Pharmaceuticals and as President of Worldwide Consumer Healthcare.